STAT8 天
Wave to submit Duchenne drug for approval after Phase 2 success
Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...
Clinical Trials Arena on MSN17 天
Dyne’s DMD trial advances patient mobility and dystrophin expression
The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an increase over baseline at 12 months.
BioSpace8 天
Wave’s Duchenne Exon-Skipper Reverses Muscle Damage in Mid-Stage Trial
WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...
Fierce Biotech8 天
Wave's DMD drug remains on track in 48-week data ahead of FDA push next year
As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...
The American Journal of Managed Care7 天
WVE-N531 Shows Functional Benefits, Muscle Damage Reversal in DMD
WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...
Yahoo Finance16 天
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients
Avidity Biosciences’ Phase I/II trial of ribonucleic acid (RNA) therapy, del-zota, has increased dystrophin in patients with Duchenne muscular dystrophy (DMD). Results from the company’s ...